Company news

Puma Biotechnology Inc news in 2022

Puma Biotechnology Inc's news releases, calls and decks from 2022, newest first.

View company

Puma Biotechnology Reports Third Quarter 2022 Financial Results

November 2, 2022

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium

October 26, 2022

Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor

September 19, 2022

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

September 10, 2022

Puma Biotechnology Reports Second Quarter 2022 Financial Results

August 3, 2022

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

May 25, 2022

Puma Biotechnology Reports First Quarter 2022 Financial Results

May 4, 2022

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

April 20, 2022

Puma Biotechnology Announces $10 Million Private Placement

March 9, 2022

Calls in 2022

Decks in 2022